US: AstraZeneca to acquire TeneoTwo for US$1.27bn

UK/Swedish global bio-pharmaceutical company, AstraZeneca, is strengthening its haematological cancer pipeline with the acquisition of US-based TeneoTwo and its Phase I clinical-stage T-cell engager, TNB-486. AstraZeneca will acquire all outstanding equity of TeneoTwo for an upfront payment of US$100m and will make additional R&D-related milestone payments of up to US$805m and commercial-related milestone payments of up…

You must be a HMI Subscriber to view this content.

Subscribe Now »